Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02340156
Recruitment Status : Terminated
First Posted : January 16, 2015
Last Update Posted : August 5, 2019
Sponsor:
Information provided by (Responsible Party):
SynerGene Therapeutics, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : November 2018
Actual Study Completion Date : November 2018